Interested in promotions? | Click here >>

Monoclonal Antibody Adenosine Deaminase Activity

Also showing Monoclonal Antibody Western Blotting Adenosine Deaminase Activity

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Monkey

Application Methods: Western Blotting

Background: Post-transcriptional processing of RNAs such as RNA editing is an important mechanism by which diversity in RNA and protein is achieved that is not otherwise encoded by the genome (1,2). The most common form of RNA editing is the conversion of adenosine (A) into inosine (I) on double stranded RNA by the adenosine deaminase acting on RNA (ADAR) family of proteins (1-3). Since inosine base pairs with cytidine, it is interpreted as a guanosine by the splicing and translational machinery leading to alteration in the protein sequence, as well as splicing isoforms being generated (1,4-6). A-to-I editing can also influence RNA sequence recognition by RNA binding proteins and non-coding RNA, such as miRNAs, affecting subsequent RNA processing, stability, and protein expression levels (2).ADAR1 is ubiquitously expressed with two known isoforms ADAR1L (p150) and ADAR1S (p110) resulting from transcription using alternative promoters and start codons. ADAR1S is constitutively expressed in the nucleus, while ADAR1L is interferon-inducible and present in both the nucleus and the cytoplasm. The induction of ADAR1L in response to cellular stress and viral infection suggests a role for RNA editing in the innate immune response (1,7). In addition, ADAR1 is essential in mammalian development, particularly in hematopoiesis and suppression of interferon signaling to protect hematopoietic stem cells from destruction in the fetal liver and the adult bone marrow (8,9).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Immunoprecipitation, Western Blotting

Background: Adenosine deaminase (ADA) catalyzes adenosine degradation (1). Lack of this enzyme leads to the accumulation of toxic metabolites causing severe combined immunodeficiency (ADA-SCID), an autosomal recessive disorder. Differentiation and function of T cells, B cells, and natural killer cells are impaired in ADA-SCID patients leading to recurrent infections (1,2). Gene therapies for ADA-SCID were reported to correct the metabolic defect and restore the deficient immune function (1-3).